Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1053-1068

  Reichardt, Peter ^a   Morosi, Carlo ^b   Wardelmann, Eva ^c   Gronchi, Alessandro ^b  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

gastrointestinal stromal tumor; medical oncologist; multidisciplinary team; pathologist; radiologist; surgeon

Indexed keywords

IMATINIB; SUNITINIB; TYROSINE KINASE RECEPTOR;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; DOCTOR PATIENT RELATION; DRUG DOSE INCREASE; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERPERSONAL COMMUNICATION; MOLECULAR DIAGNOSIS; MULTIDISCIPLINARY MANAGEMENT; ONCOGENE; ONCOGENE C KIT; PATHOLOGIST; PATIENT CARE; PDGFRA GENE; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; QUALITY OF LIFE; RADIOLOGIST; RARE DISEASE; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; SURGEON; SURVIVAL TIME; TEAMWORK; TREATMENT OUTCOME; TUMOR LOCALIZATION;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PATIENT CARE TEAM; PIPERAZINES; PREOPERATIVE PERIOD; PYRIMIDINES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84867054984     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.48     Document Type: Review

References (71)

1. Goettsch WG, Bos SD, Breekveldt-Postma N et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur. J. Cancer 41, 2868-2872 (2005).
2. Ducimetière F, Lurkin A, Ranchère-Vince D et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 6(8), e20294 (2011).
3. Mazzola P, Spitale A, Banfi S, Mazzucchelli L, Frattini M, Bordoni A. Epidemiology and molecular biology of gastrointestinal stromal tumours (GISTs): a population based study in the South of Switzerland, 1999-2005. Histol. Histopathol. 23(11), 1379-1386 (2008).
4. Mucciarini C, Rossi G, Bertolini F et al. Incidence and clinico-pathologic features of gastrointestinal stromal tumours. A population-based study. BMC Cancer 7, 230 (2007).
5. Nilsson B, Bümming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumours: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 103(4), 821-829 (2005).
6. Rubió J, Marcos-Gragera R, Ortiz MR et al. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. Eur. J. Cancer 43(1), 144-148 (2007).
7. Tryggvason G, Kristmundsson T, Orvar K et al. Clinical study on gastrointestinal stromal tumours (GIST) in Iceland, 1990-2003. Dig. Dis. Sci. 52(9), 2249-2253 (2007).
8. Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL. Epidemiology of gastrointestinal stromal tumours in a defined Canadian Health Region: a population-based study. Int. J. Surg. Pathol. 16(3), 241-250 (2008).
9. Cichoz-Lach H, Kasztelan-Szczerbinska B, Slomka M. Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol. Arch. Med. Wewn. 118(4), 216-219 (2008).
10. Rubin EJ, Sanon M, Taylor D et al. Epidemiology of surgically resected localized gastrointestinal stromal tumors (GIST) in the US. Presented at: American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 15-17 January 2009.
11. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231, 51-58 (2000).
12. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am. J. Gastroenterol. 100, 162-168 (2005).
13. McGrath PC, Neifeld JP, Lawrence W Jr et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann. Surg. 206, 706-710 (1987).
14. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. 215, 68-77 (1992).
15. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol. Int. 56(1), 1-9 (2006).
16. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics Pol. J. Pathol. 54(1), 3-24 (2003).
17. Maertens O, Prenen H, Debiec-Rychter M et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum. Mol. Genet. 15(6), 1015-1023 (2006).
18. Emile JF, Brahimi S, Coindre JM et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective populationbased study differ from those of advanced GISTs. Med. Oncol. doi:10.1007/s12032-011-0074-y (2011) (Epub ahead of print).
19. Kikuchi H, Yamashita K, Kawabata T, Yamamoto M, Hiramatsu Y, Kondo K. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. Cancer Sci. 97(2), 127-132 (2006).
20. Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus panel of experts. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v98-v102 (2010).
21. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70-83 (2006).
22. Joel KG. Gastrointestinal Stromal tumors and other mesenchymal lesions of the gut. Mod. Pathol. 16(4), 366-375 (2003).
23. Sandrasegaran K, Rajesh A, Rydberg J et al. Gastrointestinal stromal tumors: clinical, radiologic, and pathologic features. Am.J. Roentgenol. 184(3), 803-811 (2005).
24. Stamatakos M, Douzinas E, Stefanaki C et al. Gastrointestinal stromal tumor. World J Surg. Oncol. 7, 61 (2009).
25. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann. Oncol. 17(Suppl. 10), S280-S286 (2006).
26. Vander Noot MR 3rd, Eloubeidi MA, Chen VK et al. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 102(3), 157-163 (2004).
27. Montgomery E, Abraham SC, Fisher C et al. CD44 loss in gastric stromal tumors as a prognostic marker. Am. J. Surg. Pathol. 28(2), 168-177 (2004).
28. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am. J. Clin. Pathol. 103(1), 41-47 (1995).
29. Tzen CY, Mau BL. Analysis of CD117-negative gastrointestinal stromal tumors. World J. Gastroenterol. 11(7), 1052-1055 (2005).
30. Rutkowski P, Wozniak A, Debiec-Rychter M et al. Clinical utility of the new american joint committee on cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer 117(21), 4916-4924 (2011).
31. Jung SH, Suh KS, Kang DY, Kang DW, Kim YB, Kim ES. Expression of DOG1, PDGFRA, and p16 in gastrointestinal stromal tumors. Gut Liver 5(2), 171-180 (2011).
32. West R, Corless C, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 165(1), 107-113 (2004).
33. Espinosa I, Lee C, Kim M et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 32(2), 210-218 (2008).
34. Debiec-Rychter M, Dumez H, Judson I et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40(5), 689-695 (2004).
35. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
36. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
37. Casali PG, Jost L, Reichardt P et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), ii35-ii38 (2008).
38. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 39(10), 1411-1419 (2008).
39. Gold JS, Gönen M, Gutièrrez A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 10(11), 1045-1052 (2009).
40. Rossi S, Miceli R, Messerini L et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am. J. Surg. Pathol. 35(11), 1646-1656 (2011).
41. Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 13(3), 265-274 (2012).
42. Edge SB, Byrd DR, Compton CC et al. Gastrointestinal stromal tumor. In: AJCC Cancer Staging Manual (7th Edition). Edge SB, Byrd DR, Compton CC et al.(Eds). Springer, NY, USA, 175-180 (2010).
43. Knoop M, St Friedrichs K, Dierschke J. Surgical management of gastrointestinal stromal tumors of the stomach. Langenbecks Arch. Surg. 385(3), 194-198 (2000).
44. Kosmadakis N, Visvardis EE, Kartsaklis P, Tsimara M, Chatziantoniou A, Panopoulos I. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg. Oncol. 14(2), 75-84 (2005).
45. Lehnert T, Sinn HP, Waldherr R, Herfarth C. Surgical treatment of soft tissue tumors of the stomach. Eur. J. Surg. Oncol. 16(4), 352-359 (1990).
46. Demetri G. Gastrointestinal stromal tumors. In: Cancer: Principles and Practice of Oncology (8th Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 1204-1218 (2008).
47. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann. Oncol. 18(Suppl. 10), x20-x24 (2007).
48. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of primary gastrointestinal stromal tumor: a randomized, doubleblind, placebo-controlled trial. Lancet 28(373), 1097-1104 (2009).
49. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force Report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw. 5(Suppl. 2), S1-S29 (2007).
50. Joensuu H, Eriksson M, Hatrmann J et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. 29(Suppl.), (2011) (Abstract LBA1).
51. Royal College of Surgeons of England. Guidelines for the management of symptomatic breast disease. Eur. J. Surg. Oncol. 31(Suppl. 1), 1-21 (2005).
52. National Comprehensive Cancer Network, American Cancer Society. Breast Cancer Treatment Guidelines for Patients: Version VIII. American Cancer Society, GA, USA (2006).
53. Davies AR, Deans DAC, Penman I et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis. Esophagus 19(6), 496-503 (2006).
54. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK?. Lancet Oncol. 7(11), 935-943 (2006).
55. Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ. The multidisciplinary meeting: An indispensable aid to communication between different specialities. Eur. J. Cancer 42(15), 2459-2462 (2006).
56. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 93(9), 977-978 (2005).
57. Stephens MR, Lewis WG, Brewster AE et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis. Esophagus 19(3), 164-171 (2006).
58. McNair AGK, Choh CTP, Metcalfe C et al. Maximising recruitment into randomised controlled trials: The role of multidisciplinary cancer teams. Eur. J. Cancer 44(17), 2623-2626 (2008).
59. Chang AE. Multidisciplinary cancer clinics: their time has come. J. Surg. Oncol. 69(4), 203-205 (1998).
60. National Breast Cancer Centre. Multidisciplinary Meetings for Cancer Care: A Guide for Health Service Providers. National Breast Cancer Centre. Camperdown, New South Wales, Australia (2005).
61. Chang JH, Vines E, Bertsch H et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management. Cancer 91(7), 1231-1237 (2001).
62. Zorbas H, Barraclough B, Rainbird K, Luxford K, Redman S. Multidisciplinary care for women with early breast cancer in the Australian context: what does it mean?. Med. J. Aust. 179(10), 528-531 (2003).
63. National Breast Cancer Centre. Making Multidisciplinary Cancer Care a Reality, a National Breast Cancer Centre Forum Series. Report and Recommendations. National Breast Cancer Centre. Camperdown, New South Wales, Australia (2006).
64. National Breast Cancer Centre, National Cancer Control Initiative. Clinical Practice Guidelines for the Psychosocial Care of Adults with Cancer. National Breast Cancer Centre. Camperdown, New South Wales, Australia (2003).
65. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, et al. Association of plateletderived growth factor receptor a mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J. Mol. Diagn. 6(3), 197-204 (2004).
66. Kächele V, Pauls S, Mottaghy FM et al. A 25-year-old woman with a gastric GIST and a PET-positive epicardial tumor. Nat. Clin. Pract. Oncol. 4(3), 197-201 (2007).
67. Blackstein ME, Rankin C, Fletcher C et al. Clinical benefit of Imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. Presented at: American Society of Clinical Oncology. FL, USA, 13-17 May 2005 (Abstract 9010).
68. Blackstein ME, Corless CL, Ballman KV et al. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. FL, USA, 22-24 January 2010.
69. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy. Presented at: American Society of Clinical Oncology. FL, USA, 13-17 May 2005 (Abstract 9037).
70. Gronchi A, Fiore M, Bertulli R et al. Surgery of residual disease following Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). Presented at: American Society of Clinical Oncology. FL, USA, 13-17 May 2005 (Abstract 9038).
71. Reichdart P. Optimising therapy for GIST patients. Eur. J. Cancer 4(Suppl. 3), 19-26 (2006).